Welcome to our dedicated page for Paragon 28 news (Ticker: $FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Paragon 28's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Paragon 28's position in the market.
Paragon 28, a leading medical device company, reported a record net revenue of $61.1 million for the first quarter of 2024, up 17.4% from the same period in 2023. The company also reaffirmed its 2024 net revenue guidance of $249 million to $259 million, expecting 15.1% to 19.7% growth compared to 2023. Despite a decrease in gross profit margin and an increase in operating expenses, the company remains optimistic about sustainable growth driven by new product launches and expanded commercial channels.
Paragon 28, Inc. (NYSE: FNA) will be presenting at the Bank of America Securities 2024 Healthcare Conference. The Chairman and CEO, Albert DaCosta, and Interim CFO, Krissy Wright, will participate in a fireside chat on May 14, 2024. The event will be live webcasted and archived on the investor relations section of the Company's website.